OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Leukemia: A Review of Data from the ASH 2022 Meeting

home / the-talk / leukemia-a-review-of-data-from-the-ash-2022-meeting

Expert hematologist/oncologists review key datasets in leukemia presented at the ASH 2022 Annual Meeting.

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.

Elias Jabbour, MD, an expert on leukemia

EP. 1: ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

By Sameem Abedin, MD
Elias Jabbour, MD
  • Harry Erba, MD, PhD
  • Anjali Advani, MD
February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Anjali Advani, MD, an expert on leukemia

EP. 2: ASH 2022: Recent Advances in Chronic Myeloid Leukemia

By Sameem Abedin, MD
Elias Jabbour, MD
  • Harry Erba, MD, PhD
  • Anjali Advani, MD
February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Harry Erba, MD, PhD, an expert on leukemia

EP. 3: Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

By Sameem Abedin, MD
Elias Jabbour, MD
  • Harry Erba, MD, PhD
  • Anjali Advani, MD
February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Latest Conference Coverage

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact